Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11098564 | 0.86 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL13199726 | 0.86 | AGTR2 (0.59) | AGTR1AGTR2 | |
| SCHEMBL1569312 | 0.85 | AGTR1 (0.67) | AGTR1AGTR2 | |
| SCHEMBL11102028 | 0.83 | AGTR1 (0.65) | AGTR1AGTR2 | |
| SCHEMBL11269513 | 0.83 | AGTR1 (0.80) | AGTR1AGTR2 | |
| SCHEMBL10535973 | 0.82 | AGTR1 (0.73) | AGTR1AGTR2 | |
| SCHEMBL430 | 0.82 | AGTR1 (0.73) | AGTR1AGTR2 | |
| SCHEMBL11099156 | 0.82 | AGTR1 (0.62) | AGTR1AGTR2 | |
| SCHEMBL11090560 | 0.81 | AGTR1 (0.61) | AGTR1AGTR2 | |
| SCHEMBL11097020 | 0.81 | AGTR1 (0.61) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132437-B2 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE (US) | 2006-11-07 | — | — | US | disclosed |
| US-6984633-B2 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and epoxymexrenone | G.D SEARLE & CO. (US) | 2006-01-10 | — | — | US | disclosed |
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO., | 2004-11-04 | — | — | US | disclosed |
| CN-1522701-A | Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy | G.D.ɪ����˾ | 2004-08-25 | — | — | CN | disclosed |
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-06-24 | — | — | US | disclosed |
| US-20040102423-A1 | Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
| US-20040067915-A1 | Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone | G.D. SEARLE & CO. (US) | 2004-04-08 | — | — | US | disclosed |
| CN-1142793-C | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure | G��D��ɪ����˾ | 2004-03-24 | — | — | CN | disclosed |
| US-20040053903-A1 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist | G.D. SEARLE & CO. | 2004-03-18 | — | — | US | disclosed |
| US-5140036-A | Hypotensive agents; congestive heart failure; angiotensin antagonists | G. D. SEARLE & CO. (US) | 1992-08-18 | — | — | US | disclosed |
| WO-1992011255-A1 | N-SUBSTITUTED N-(α-TRIAZOLYL-TOLUYL)PYRROLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-07-09 | — | — | WO | disclosed |
| WO-1992007834-A1 | N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| WO-1992007852-A1 | BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| WO-1992005161-A1 | 1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-04-02 | — | — | WO | disclosed |
| US-5098920-A | Hypotensive agents and treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 1992-03-24 | — | — | US | disclosed |
| WO-1992004335-A2 | RENAL-SELECTIVE BIPHENYLALKYL 1H-SUBSTITUTED-1,2,4-TRIAZOLE ANGIOTENSIN II ANTAGONISTS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1991019715-A1 | 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-26 | — | — | WO | disclosed |
| WO-1991018888-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-12 | — | — | WO | disclosed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067915-A1 | Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone | AGTR2, AGTR1, NR3C2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20040102423-A1 | Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure | AGTR2, AGTR1, NR3C2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | AGTR1 2/4885AGTR2 3/4885 |
| US-20040053903-A1 | Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist | NR3C2, AGTR2, AGTR1 | AGTR1 3/4885AGTR2 2/4885 |
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | AGTR1 2/4885AGTR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.